OncRef

Clinical Trial: NCT05364073

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 1

Lead Sponsor:ArriVent BioPharma, Inc.
Information Provided By:ArriVent BioPharma, Inc.
Last Update Posted:2026-11-12

Study Overview

Brief Summary

This is a Phase 1b, open-label, multi-center, dose-escalation and dose expansion study designed to evaluate the safety, pharmacokinetics (PK), and preliminary antitumor activity of furmonertinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) with activating, including uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) mutations. Patients will be enrolled into one of 2 stages: Stage 1 (Dose Escalation and Backfill Cohorts) and Stage 2 (Dose Expansion).

Official Title

A Phase 1b Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Antitumor Activity of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

Conditions

Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, HER2 Exon 20 Mutations, EGFR Exon 20 Mutations, EGFR Uncommon Mutations, Including G719X and S768I

Intervention / Treatment

  • Drug: Furmonertinib
  • Drug: Furmonertinib
  • Drug: Furmonertinib
  • Drug: Furmonertinib
  • Drug: Furmonertinib

Other Study ID Numbers

  • FURMO-002

Start Date (Actual)

2022-06-30

Primary Completion Date (Actual)

2025-06-03

Study Completion Date (Estimated)

2026-12-31

Enrollment (Actual)

160

Study Type

Interventional

Phase

Phase 1